Correspondence on ‘Characteristics of second primary malignancies following bispecific antibodies therapy by Liang et al
We commend Lianget al for shining a spotlight on second primary malignancies after bispecific antibody (BsAb) therapy, yet several clinical nuances deserve consideration. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)-derive…